Dive Into Dollar Tr...
Health Care: Drugs
Teva Pharmaceutical Industries Ltd (TEVA: NYSE)
$40.23 0.27 | 0.68%
05/17/13 - 04:03 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 1.91B | 2.77B | 3.34B | 2.00B |
| Operating Gains/Losses | -3.00M | -207.00M | 0.00 | 23.00M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 936.00M | 704.00M | -362.00M | -181.00M |
| (Increase) Decrease in Inventories | -449.00M | -410.00M | -16.00M | 163.00M |
| (Increase) Decrease In Other Current Assets | -54.00M | -240.00M | 51.00M | 0.00 |
| (Decrease) Increase In Payables | -19.00M | 543.00M | -295.00M | 463.00M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 369.00M | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 1.23B | 407.00M | 272.00M | 133.00M |
| Net Cash From Continuing Operations | 4.57B | 4.13B | 4.14B | 3.37B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 4.57B | 4.13B | 4.14B | 3.37B |
| Sale of Property, Plant & Equipment | 264.00M | 279.00M | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -1.10B | -1.05B | -710.00M | -719.00M |
| Acquisitions | 0.00 | -6.56B | -4.95B | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -93.00M | -49.00M | 29.00M | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.13B | -7.60B | -5.46B | -916.00M |
| Issuance of Debt | 1.24B | 6.72B | 4.04B | 445.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 14.00M | 71.00M | 180.00M | 169.00M |
| Repayment of Long-Term Debt | -2.21B | -1.56B | -2.85B | -2.33B |
| Repurchase of Capital Stock | -1.16B | -899.00M | -99.00M | 0.00 |
| Payment of Cash Dividends | -855.00M | -800.00M | -668.00M | -528.00M |
| Other Financing Charges, Net | 1.30B | -194.00M | -30.00M | -24.00M |
| Net Cash From Financing Activities | -1.68B | 3.34B | 573.00M | -2.26B |
| Effect of Exchange Rate Changes | 23.00M | -21.00M | -1.00M | -51.00M |
| Net Change in Cash & Cash Equivalents | 1.78B | -152.00M | -747.00M | 141.00M |
Portfolios with TEVA
- Portfolio NameUser Type
- UserDonnie Portfolio 2 High Grade
- UserMain
- UserLong Term Stock Picks
- UserTRIG
- Userfun and games
- Userabangser Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- Contributor8 Pharma Stocks to Watch
- Userdividend
- UserIncome stocks
Latest TEVA Headlines from TheStreet
- 4 Stocks Improving Performance Of The Health Care Sector 05.16.13 | 01:05 pm
- 5 Stocks Going Ex-Dividend Tomorrow: LAND, RNDY, TROX, R, TEVA 05.15.13 | 10:05 am
- Teva Stock To Go Ex-dividend Tomorrow (TEVA) 05.15.13 | 09:05 am
- Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Health Care Winner 05.14.13 | 05:05 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 05.10.13 | 10:05 am
- 'Mad Money' Lightning Round: Buy, Buy, Buy Biogen 05.10.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Looking for Real Leaders 05.09.13 | 08:05 pm
- 5 Stocks Advancing The Drugs Industry 05.07.13 | 01:05 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 04.29.13 | 10:04 am
- Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner 04.24.13 | 05:04 pm
Press Releases for TEVA
- Alexza Announces Conference Call To Discuss Agreement With Teva To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- Teva And Alexza Announce Teva's License To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- OncoGenex Announces Plans For The Initiation Of The Rainier⿢ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer - PR Newswire 05.01.13 | 06:05 am
- OncoGenex Announces That The Borealis-2â¿¢ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment - PR Newswire 04.30.13 | 08:04 am
- More Than Half Of Nasal Allergy Sufferers Experience Sleep Issues, Yet Many Fail To Adequately Prepare In Advance Of Peak Allergy Seasons - PR Newswire 04.23.13 | 08:04 am
- Apolo Anton Ohno And Teva Respiratory Announce Finalists In National EIB All Starsâ¿¢ Contest - PR Newswire 04.16.13 | 08:04 am
- OncoGenex Announces Plans For The Initiation Of The Spruceâ¿¢ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer - PR Newswire 04.11.13 | 08:04 am
- Early Versus Delayed Treatment With Laquinimod Demonstrated Significant Reduction In Risk Of Disability Progression – Results Of Three-Year ALLEGRO Study In Relapsing-Remitting Multiple Sclerosis - Business Wire 03.21.13 | 08:03 am
- New Data Show Azilect® (rasagiline Tablets) Provided Clinical Benefit In Patients With Early Parkinson’s When Added To Sub-Optimally Controlled Patients On Dopamine Agonist Therapy - Business Wire 03.20.13 | 07:03 am
- Teva To Present New Research On CNS Product Portfolio And Pipeline At 2013 American Academy Of Neurology Annual Meeting - Business Wire 03.14.13 | 09:03 am
Partner Headlines for TEVA
- Analysts: SanDisk Will Beat Estimates and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- FDA Approves NDA for Teva's Quartette Tablets to Prevent Pregnancy - Benzinga 03.29.13 | 11:03 am
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- Biogen MS Drug Approved; No 'Black Box' Label - Investor's Business Daily 03.27.13 | 06:03 pm
- Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind - Seeking Alpha 03.25.13 | 09:03 am
- Valeant Earnings, Sales Top Estimates; Street Shrugs - Investor's Business Daily 02.28.13 | 05:02 pm
- 3 Industries Set To Profit From An Aging Population - Seeking Alpha 01.31.13 | 09:01 am
- Amgen Q4 Sales, 2013 Guidance Modestly Beat Estimates - Investor's Business Daily 01.23.13 | 06:01 pm
- Teva Pharmaceuticals - Food For Thought - Seeking Alpha 01.15.13 | 08:01 am
